Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05537948 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients

Study acronym: PINTL
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 80 to confirmed 59
    • Primary completion date changed from estimate of Jun 30, 2024 to Jan 31, 2024
    • Site details revised
    v4
  2. Primary completion date: Dec 25, 2023 to Jun 30, 2024
    • Study completion date: Dec 31, 2023 to Jan 31, 2025
    v3
  3. Primary completion date: Sep 1, 2023 to Dec 25, 2023v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To study the efficacy and safety of pitavastatin and PCSK9 inhibitors in liver transplant patients on ongoing immunosuppressive therapy.
Trial Details
NCT Number NCT05537948
Lead Sponsor National Medical Research Center for Therapy and Preventive Medicine
Conditions
(from sponsor)		 Dyslipidemias, Hyperlipidemias, Liver Transplant Disorder, Immunosuppression, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Statins
Related terms Dyslipidemias, Hyperlipidemias
Enrollment 59 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov